Lutikizumab (AbbVie), an investigational dual-variable-domain interleukin (IL)-1α/1β antagonist, performed well in adults and adolescents with moderate-to-severe hidradenitis suppurativa (HS), according to top-line results from the Phase 3 INTREPID study.
In the study, HS patients treated with lutikizumab achieved significantly higher Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) response rates at Week 16 compared with placebo: 31.4% vs. 23.4%, respectively.
“This Phase 3 data reinforces the observations from the smaller earlier Phase 2 programs: IL-1α/β blockade with lutikizumab produces clinical improvements in patients with HS, using a different approach than the current array of approved treatments,” says Alexa B. Kimball, MD, MPH, President and CEO of Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center, Boston, and Professor of Dermatology at Harvard Medical School in Boston, MA, in an interview with The Dermatology Digest® (TDD).
Lutikizumab also demonstrated statistically significant improvements across key ranked secondary endpoints, including rapid reductions in HS-related pain and significantly fewer HS flares, compared to placebo. At Week 8, 26.2% of patients treated with lutikizumab achieved NRS3, defined as at least a three-point reduction from baseline in HS-related skin pain on the Numeric Rating Scale (NRS), compared with 15.0% of patients receiving placebo. Improvements in NRS3 were reported as early as Week 1.
In addition, at Week 8, 36.0% of patients receiving lutikizumab achieved NRS30, defined as at least a 30% reduction and at least a two-unit reduction from baseline in HS-related skin pain, compared with 22.8% of patients receiving placebo. Lutikizumab also significantly reduced the occurrence of HS flares during the first 16 weeks compared with placebo (18.4% vs. 28.1% patients experienced flares).
Additional improvements were observed in quality-of-life measures, including changes from baseline in the Dermatology Life Quality Index (DLQI) and Hidradenitis Suppurativa Impact Assessment (HSIA). Key potential disease drivers, including IL-17A and IL-17F levels, were also reduced over the double-blind 16-week treatment period. These findings reinforce the potential for lutikizumab to address the burden of disease for people living with moderate-to-severe HS.
New MOA for Treating HS
Lutikizumab works by neutralizing both IL-1α and IL-1β, which are important elements found early in the inflammatory cascade. “While we are still working out the details of the pathways, we know that IL-1α and IL-1β are elevated in HS lesions,” Dr. Kimball says. “They also drive neutrophil-rich inflammation, which is a major HS feature, and drive other important parts of key inflammatory pathways.”
The safety profile of lutikizumab was similar to prior studies, with no new safety concerns identified. Overall, treatment-emergent adverse event (TEAE) rates were similar with lutikizumab and placebo: any adverse event (AE) (53.4% vs. 53.7%), any serious AE (3.0% vs. 2.9%), and AEs leading to discontinuation (1.7% vs. 1.9%), respectively. The most frequently reported TEAEs associated with lutikizumab (≥3%) were nasopharyngitis, upper respiratory tract infections, headache, fatigue, and injection-site reactions. Except for injection-site reactions, their rates were similar to placebo. Similar rates of oral candidiasis were also observed between the lutikizumab and placebo groups (0.3% vs. 0.4%, respectively). There was no suicidal ideation observed in either the lutikizumab or placebo group. There were no deaths in the lutikizumab group; one death occurred in the placebo group.
The Bigger Picture in HS
“HS is chronic, painful, and disabling—and often diagnosed after substantial delays,” she says. “We are increasingly understanding that those delays result in more progressive and less reversible disease, especially as patients develop infiltrating scarring patterns.”
Anecdotally, surgeons are increasingly telling us that they want HS “calmed down” with medical therapy before they do surgery, because it leads to better outcomes. “In the future, if we treat people earlier and more effectively, we may need less surgery, because the disease we treat will be more reversible,” Dr. Kimball says.
These data will be presented at a future medical congress. Additional data from the Phase 3 INTREPID study, including results from a 36-week blinded extension period, are expected in 2027 and will be used to support regulatory submissions for lutikizumab in HS in the second half of the year.
PHOTO CREDIT: DermNet